About Aravis
Aravis is a private equity firm founded in 2001. It is primarily based in Zurich, Switzerland. As of May 2026, Aravis has a portfolio of 23 companies, comprising 23 funding rounds and 1 acquisition. The firm primarily invests in companies based in United States and Switzerland. Its portfolio is spread across a wide range of sectors from Life Sciences to Healthcare. Its latest investment was a $***** Series A round in Hedera-22 on Aug 14, 2024 which also saw participation from Gesval and Noshaq.
Overall Aravis portfolio has seen 1 unicorn, 3 IPOs and 10 acquisitions including key companies like CASI Pharmaceuticals, Ambrx and Omeros. A lot of funds co-invest with Aravis, with names like Novartis Venture Fund sharing a substantial percentage of its portfolio.
Aravis has a team of 7 people, including 3 partners.
Key Metrics
Founded Year
2001
Location
Zurich, Switzerland
Portfolio Companies
Portfolio Sectors
Portfolio Locations
Acquisition Deals
Investment Deals
Aravis' Portfolio
Aravis has a portfolio of 23 companies. They have invested in a total of 23 companies. Their most recent investment was in Hedera-22 (Series A round) on Aug 14, 2024. Here is the most recent investment by Aravis:Date | Company | Round | Amount | Co-Investors |
|---|---|---|---|---|
Aug 14, 2024 | Series A | 4669 | ||
Mar 25, 2014 | Series B | 9105 | and 5 others | |
Feb 18, 2014 | Series A | 1717 | ||
Dec 02, 2013 | Series B | 9045 |
Aravis has acquired 1 company. Their most recent acquisition was of AGI Therapeutics on Jan 09, 2012. Here is the most recent acquisition by Aravis:
Acquisition Date | Company | Short Description | Total Funding | Founded Year |
|---|---|---|---|---|
Jan 09, 2012 | Develops drug products for lung-related conditions | - | 2005 |
Here is the portfolio snapshot of Aravis:
Investments by Year
The maximum number of investments were made in 2024
Portfolio by Location
Companies are primarily in United States and Switzerland
Portfolio by Sector
Companies are primarily in Life Sciences
Team profile of Aravis
Aravis has a team of 7 members including 3 Partners and 1 Venture Partner located in Switzerland and Thailand. Aravis' team does not sit on the board of any company as of now.Here is a list of all team members in Aravis:
Name | Designation | Location | Board Memberships | Contact Details |
|---|---|---|---|---|
Partner | Zurich | - | ||
Partner | Zurich | - | ||
Partner | Zurich | - | - | |
Venture Partner | Bangkok | - | - | |
Analyst | Zurich | - | - |
Co-investors of Aravis
Over the past 25 years, 39 investors have co-invested in Aravis's portfolio companies.
- Top Co-investors of Aravis: 39 investors entered a company along with Aravis. These include investors like Novartis Venture Fund (6 companies).
Aravis News
•
Telormedix raises $6.6m from Aravis and Proquest | UnquoteUnquote•Dec 02, 2013•Telormedix, ProQuest Investments, Aravis
•
Synosia Therapeutics Raises CHF32 Million in Series B Private Financing | FierceBiotechFierce Biotech•Jan 07, 2009•Synosia Therapeutics, Investor, Versant Ventures, Abingworth and 4 others
•
S*BIO Completes US$26 Million Equity Financing | FierceBiotechFierce Biotech•Oct 20, 2008•Sbio, 5AM Ventures, Zurcher Kantonalbank, Adamant Biomedical Investments and 2 others
•
•
PE Week Wire - Friday, April 29 - PE HubPE Hub•Apr 29, 2005•Ikaria, Arch Venture Partners, 5AM Ventures, Venrock and 9 others
•
Ikaria Inc. Launched by ARCH Venture Partners, Venrock Associates, 5AM Ventures and Fred Hutchinson Cancer Research Center; Company will develop commercial applications for reversible metabolic control technology | Business WireBusiness Wire•Apr 26, 2005•Ikaria, Arch Venture Partners, 5AM Ventures, Venrock and 2 others
•
PR Newswire•Aug 04, 2004•Kalypsys, Tavistock Group, Novartis Venture Fund, CMEA Ventures and 4 others
•
Kalypsys Gets $43 Million in First Round - WSJThe Wall Street Journal•Apr 02, 2002•Kalypsys, Tavistock Group, CMEA Ventures, Lombard Odier and 5 others
•
